NCT01173497 - A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

July 31, 2013

Conditions

Estrogen Receptor Negative (ER-Negative) Breast CancerProgesterone Receptor Negative (PR-Negative) Breast CancerHuman Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast CancerBrain Metastases

Interventions

DRUG

INIPARIB + irinotecan

21 day cycle

Trial Locations (13)

Unknown

University of Alabama At Birmingham, Birmingham

University of California At San Francisco, San Francisco

Georgetown University, Washington D.C.

University of Chicago, Chicago

Indiana University Simon Cancer Center, Indianapolis

Johns Hopkins University, Baltimore

Dana Farber Cancer Institute, Boston

University of Michigan, Ann Arbor

Duke University, Durham

University of Pittsburgh Medical Center, Pittsburgh

Vanderbilt University, Nashville

MD Anderson Cancer Center, Houston

27599-7295

University of North Carolina-CH Lineberger Comprehensive Cancer Center, Chapel Hill